SQNM SEC-arkivering - Sequenom, Inc.- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

CIK

1076481

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sequenom, Inc.

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

January 12, 2017	SC 13G/A	SQNM / Sequenom, Inc. / Palo Alto Investors, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) Sequenom Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 817337405 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i
September 23, 2016	15-12G	Sequenom FORM 15-12G Form 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-29101 SEQUENOM, INC. (Exact name of registrant as specified
September 15, 2016	POS AM	Sequenom POS AM POS AM As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	POS AM	Sequenom POS AM POS AM 1 d251077dposam.htm POS AM As filed with the Securities and Exchange Commission on September 15, 2016 Registration No. 333-147146 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 77-0365889 (S
September 15, 2016	POS AM	Sequenom POS AM POS AM As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	POS AM	Sequenom POS AM POS AM As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS 1 d259953ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No. 333-189520 Registration No. 333-182911 Registration No. 333-175513 Registration No. 333-172302 Registration No. 333-167831 Registration No. 333-152230 Registration No. 333-134906 Registration No. 333-125456 Registration No. 333-112322 Registration No. 333-102769 Registrat
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS 1 d259953ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No. 333-189520 Registration No. 333-182911 Registration No. 333-175513 Registration No. 333-172302 Registration No. 333-167831 Registration No. 333-152230 Registration No. 333-134906 Registration No. 333-125456 Registration No. 333-112322 Registration No. 333-102769 Registrat
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 15, 2016	S-8 POS	Sequenom S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 15, 2016 Registration No.
September 7, 2016	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 d252942d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2016 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of inc
September 7, 2016	EX-3.2	SEQUENOM, INC. AMENDED AND RESTATED BYLAWS EFFECTIVE AS OF SEPTEMBER 7, 2016 AMENDED AND RESTATED BYLAWS SEQUENOM, INC. EX-3.2 3 d252942dex32.htm EX-3.2 Exhibit 3.2 SEQUENOM, INC. AMENDED AND RESTATED BYLAWS EFFECTIVE AS OF SEPTEMBER 7, 2016 AMENDED AND RESTATED BYLAWS OF SEQUENOM, INC. 1. OFFICES 1.1 Registered Office The initial registered office of the Corporation in the State of Delaware shall be at 2711 Centerville Road, Suite 400 in Wilmington, County of New Castle, Delaware 19808. The name of the initial reg
September 7, 2016	EX-4.1	SEQUENOM, INC. AS ISSUER 5.00% CONVERTIBLE SENIOR NOTES DUE 2017 First Supplemental Indenture Dated as of September 7, 2016 to Indenture Dated as of September 17, 2012 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE EX-4.1 Exhibit 4.1 SEQUENOM, INC. AS ISSUER 5.00% CONVERTIBLE SENIOR NOTES DUE 2017 First Supplemental Indenture Dated as of September 7, 2016 to Indenture Dated as of September 17, 2012 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE FIRST SUPPLEMENTAL INDENTURE dated as of September 7, 2016 (this ?Supplemental Indenture?), by and between Sequenom, Inc., a Delaware corporation (the ?Company?),
September 7, 2016	EX-4.2	SEQUENOM, INC. AS ISSUER 5.00% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2018 First Supplemental Indenture Dated as of September 7, 2016 to Indenture Dated as of June 9, 2015 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE EX-4.2 5 d252942dex42.htm EX-4.2 Exhibit 4.2 SEQUENOM, INC. AS ISSUER 5.00% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2018 First Supplemental Indenture Dated as of September 7, 2016 to Indenture Dated as of June 9, 2015 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE FIRST SUPPLEMENTAL INDENTURE dated as of September 7, 2016 (this “Supplemental Indenture”), by and between Sequenom, Inc., a Delaware
September 7, 2016	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SEQUENOM, INC. ARTICLE I. EX-3.1 2 d252942dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SEQUENOM, INC. ARTICLE I. Name The name of the corporation is Sequenom, Inc. (the “Corporation”). ARTICLE II. Registered Office The registered office of the Corporation in the State of Delaware shall be located at 2711 Centerville Road, Suite 400 in the City of Wilmington, County of New Castle, Delawa
September 7, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 7) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
September 7, 2016	SC TO-T/A	Sequenom SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 6) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sequenom, Inc. (Name of Subject Company (Issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (Offeror)) Common Stock, par value $0.001
September 7, 2016	EX-24	POWER OF ATTORNEY EX-24 2 haaspoa.htm POWER OF ATTORNEY POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints F. Samuel Eberts III attorney-in-fact and agent, in connection with the filing for the undersigned on Form 3, Form 4, and Form 5 under the Securities Act of 1934, as amended, including, without limiting the generality of the foregoing, to sign the Form 3, Fo
September 7, 2016	SC 13D/A	SQNM / Sequenom, Inc. / Camber Capital Management LLC - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sequenom, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 817337405 (CUSIP Number) Camber Capital Management LLC, 101 Huntington Avenue, Suite 2101, Boston, MA 02199 617-717-6600 (Name, Address and Telephone Number of
September 7, 2016	EX-24	POWER OF ATTORNEY EX-24 2 eisenbergpoa.htm POWER OF ATTORNEY POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints F. Samuel Eberts III attorney-in-fact and agent, in connection with the filing for the undersigned on Form 3, Form 4, and Form 5 under the Securities Act of 1934, as amended, including, without limiting the generality of the foregoing, to sign the Form
September 7, 2016	EX-24	POWER OF ATTORNEY EX-24 2 vandervaartpoa.htm POWER OF ATTORNEY POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints F. Samuel Eberts III attorney-in-fact and agent, in connection with the filing for the undersigned on Form 3, Form 4, and Form 5 under the Securities Act of 1934, as amended, including, without limiting the generality of the foregoing, to sign the For
September 7, 2016	EX-24	POWER OF ATTORNEY EX-24 2 millerpoa.htm POWER OF ATTORNEY POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints F. Samuel Eberts III attorney-in-fact and agent, in connection with the filing for the undersigned on Form 3, Form 4, and Form 5 under the Securities Act of 1934, as amended, including, without limiting the generality of the foregoing, to sign the Form 3,
August 30, 2016	SC TO-T/A	Sequenom SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 5) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sequenom, Inc. (Name of Subject Company (Issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (Offeror)) Common Stock, par value $0.001
August 30, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 6) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
August 26, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
August 26, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
August 26, 2016	SC TO-T/A	Sequenom SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sequenom, Inc. (Name of Subject Company (Issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (Offeror)) Common Stock, par value $0.001
August 26, 2016	SC TO-T/A	Sequenom SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sequenom, Inc. (Name of Subject Company (Issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (Offeror)) Common Stock, par value $0.001
August 26, 2016	EX-99.(A)(7)	Employee Questions and Answers Regarding the Proposed Merger with LabCorp EX-99.(A)(7) 2 d249152dex99a7.htm EX-99.(A)(7) Exhibit (a)(7) Employee Questions and Answers Regarding the Proposed Merger with LabCorp What has happened? LabCorp and Sequenom have entered into a definitive merger agreement under which we anticipate that LabCorp will acquire Sequenom following the conclusion of a cash tender offer to purchase all outstanding shares of Sequenom’s common stock and a
August 26, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
August 26, 2016	EX-99.(A)(7)	Employee Questions and Answers Regarding the Proposed Merger with LabCorp EX-99.(A)(7) 2 d249152dex99a7.htm EX-99.(A)(7) Exhibit (a)(7) Employee Questions and Answers Regarding the Proposed Merger with LabCorp What has happened? LabCorp and Sequenom have entered into a definitive merger agreement under which we anticipate that LabCorp will acquire Sequenom following the conclusion of a cash tender offer to purchase all outstanding shares of Sequenom’s common stock and a
August 26, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
August 23, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A 1 d245096dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title
August 23, 2016	SC TO-T/A	Sequenom SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or Section 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Sequenom, Inc. (Name of Subject Company (issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (Offeror)) Common Stock, par value $0.001 per share,
August 23, 2016	EX-99.A.5.C	LABCORP’S ACQUISITION OF SEQUENOM CLEARS ANTITRUST REVIEW EX-99.A.5.C 2 d228076dex99a5c.htm EX-A.5.C Exhibit (a)(5)(c) Laboratory Corporation of America® Holdings 358 South Main Street Burlington, NC 27215 Telephone: (336) 584-5171 www.labcorp.com FOR IMMEDIATE RELEASE Contact: Paul Surdez (investors) – 336-436-5076 [email protected] Pattie Kushner (media) – 336-436-8263 [email protected] LABCORP’S ACQUISITION OF SEQUENOM CLEARS ANTITRUST REVIEW Burli
August 22, 2016	SC 13G	SQNM / Sequenom, Inc. / QVT Financial LP - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sequenom, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 817337405 (CUSIP Number) August 11, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
August 22, 2016	SC 13G	SQNM / Sequenom, Inc. / QVT Financial LP - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sequenom, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 817337405 (CUSIP Number) August 11, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
August 19, 2016	SC TO-T/A	Sequenom SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or Section 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Sequenom, Inc. (Name of Subject Company (issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (offeror)) Common Stock, par value $0.001
August 19, 2016	SC TO-T/A	Sequenom SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or Section 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Sequenom, Inc. (Name of Subject Company (issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (offeror)) Common Stock, par value $0.001
August 19, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
August 19, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
August 16, 2016	SC TO-T/A	Sequenom SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Sequenom, Inc. (Name of Subject Company (Issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (Offeror)) Common Stock, par value $0.001
August 16, 2016	SC 14D9/A	Sequenom SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 81733740
August 9, 2016	SC 14D9	Sequenom SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 9, 2016	EX-99.A.1.D	Offer to Purchase for Cash All Outstanding Shares of Common Stock Sequenom, Inc. $2.40 Net Per Share in Cash Pursuant to the Offer to Purchase Dated August 9, 2016 Savoy Acquisition Corp. a direct wholly owned subsidiary of Laboratory Corporation of EX-99(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Sequenom, Inc.
August 9, 2016	EX-99.A.1.A	Offer to Purchase for Cash All Outstanding Shares of Common Stock, and Associated Preferred Stock Purchase Rights, of Sequenom, Inc. $2.40 Net Per Share in Cash Savoy Acquisition Corp. a direct wholly owned subsidiary of Laboratory Corporation of Ame EX-99.A.1.A 2 d237412dex99a1a.htm EX-99.(A)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock, and Associated Preferred Stock Purchase Rights, of Sequenom, Inc. at $2.40 Net Per Share in Cash by Savoy Acquisition Corp. a direct wholly owned subsidiary of Laboratory Corporation of America Holdings THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE
August 9, 2016	EX-99.A.1.F	This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase (as defined below), the related Letter of Transmittal, a EX-99(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).
August 9, 2016	SC TO-T	Sequenom SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sequenom, Inc. (Name of Subject Company (Issuer)) Savoy Acquisition Corp. Laboratory Corporation of America Holdings (Name of Filing Persons (Offeror)) Common Stock, par value $0.001 per share, an
August 9, 2016	EX-99.D.3	CONFIDENTIALITY AGREEMENT EX-99(d)(3) Exhibit (d)(3) CONFIDENTIALITY AGREEMENT This CONFIDENTIAL AGREEMENT (?Agreement?) is being entered into as of October 23, 2015 between Sequenom, Inc.
August 9, 2016	EX-99.A.1.B	Letter of Transmittal To Tender Shares of Common Stock SEQUENOM, INC. at $2.40 Net Per Share in Cash Pursuant to the Offer to Purchase dated August 9, 2016 by Savoy Acquisition Corp., a direct wholly owned subsidiary of Laboratory Corporation of Amer EX-99.A.1.B 3 d237412dex99a1b.htm EX-99(A)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of SEQUENOM, INC. at $2.40 Net Per Share in Cash Pursuant to the Offer to Purchase dated August 9, 2016 by Savoy Acquisition Corp., a direct wholly owned subsidiary of Laboratory Corporation of America Holdings The undersigned represents that I (we) have full authority to surre
August 9, 2016	EX-99.A.1.C	Notice of Guaranteed Delivery Offer to Purchase for Cash All Outstanding Shares of Common Stock Sequenom, Inc. $2.40 Net Per Share in Cash Pursuant to the Offer to Purchase Dated August 9, 2016 Savoy Acquisition Corp. a direct wholly owned subsidiary EX-99.A.1.C 4 d237412dex99a1c.htm EX-99(A)(1)(C) Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of Sequenom, Inc. at $2.40 Net Per Share in Cash Pursuant to the Offer to Purchase Dated August 9, 2016 by Savoy Acquisition Corp. a direct wholly owned subsidiary of Laboratory Corporation of America Holdings THE OFFER AND WITHDRAWA
August 9, 2016	EX-99.A.1.E	Offer to Purchase for Cash All Outstanding Shares of Common Stock Sequenom, Inc. $2.40 Net Per Share in Cash Pursuant to the Offer to Purchase Dated August 9, 2016 Savoy Acquisition Corp. a direct wholly owned subsidiary of Laboratory Corporation of EX-99.A.1.E 6 d237412dex99a1e.htm EX-99(A)(1)(E) Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Sequenom, Inc. at $2.40 Net Per Share in Cash Pursuant to the Offer to Purchase Dated August 9, 2016 by Savoy Acquisition Corp. a direct wholly owned subsidiary of Laboratory Corporation of America Holdings THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:01 A.M.
August 9, 2016	EX-99.A.5.B	LabCorp Commences Cash Tender Offer for All Outstanding Shares of Sequenom, Inc. EX-99.A.5.B 8 d237412dex99a5b.htm EX-99(A)(5)(B) Exhibit (a)(5)(B) FOR IMMEDIATE RELEASE LabCorp Contact: Paul Surdez, Vice President, Investor Relations (investors) 336-436-5076 [email protected] Pattie Kushner, Vice President, Corporate Communications (media) 336-436-8263 [email protected] LabCorp Commences Cash Tender Offer for All Outstanding Shares of Sequenom, Inc. BURLINGTON, N.C. August
August 5, 2016	10-Q	Sequenom FORM 10-Q (Quarterly Report) 10-Q 1 sqnm2016q210q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
July 27, 2016	SC TO-C	Sequenom SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement under Section 14(d)(1) or Section 13(e)(1) of the Securities Exchange Act of 1934 Sequenom, Inc. (Name of Subject Company (Issuer)) Savoy Acquisition Corp. a direct wholly owned subsidiary of Laboratory Corporation of America Holdings (Name of Filing Persons (Offeror))
July 27, 2016	EX-99.A.5.A	LABCORP ANNOUNCES AGREEMENT TO ACQUIRE SEQUENOM Acquisition Creates Market Leader in NIPT, Women’s Health and Reproductive Genetics LabCorp CEO: ‘This is exactly the kind of strategic acquisition that LabCorp seeks’ EX-99.A.5.A 2 d200168dex99a5a.htm EX-99.A.5.A Exhibit (a)(5)(A) FOR IMMEDIATE RELEASE LabCorp Contact: Paul Surdez, Vice President, Investor Relations (investors) 336-436-5076 [email protected] Pattie Kushner, Vice President, Corporate Communications (media) 336-436-8263 [email protected] Sequenom Contact: Carolyn Beaver, Senior Vice President and Chief Financial Officer (investors) 858-202-902
July 27, 2016	EX-99.A.5.B	Laboratory Corporation of America Holdings Second Quarter 2016 Earnings Conference Call Wednesday, July 27, 2016, at 9:00 A.M. Eastern Time Transcript Excerpts Related to the Proposed Acquisition of Sequenom, Inc. EX-99.A.5.B 3 d200168dex99a5b.htm EX-99.A.5.B Exhibit (a)(5)(B) Laboratory Corporation of America Holdings Second Quarter 2016 Earnings Conference Call Wednesday, July 27, 2016, at 9:00 A.M. Eastern Time Transcript Excerpts Related to the Proposed Acquisition of Sequenom, Inc. Dave King—Laboratory Corporation of America Holdings—Chairman and CEO [Unrelated discussion] This morning is exciting, as
July 27, 2016	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits 8-K 1 d200306d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2016 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorpo
July 27, 2016	EX-4.1	AMENDMENT NO. 1 TO RIGHTS AGREEMENT EX-4.1 3 d200306dex41.htm EX-4.1 Exhibit 4.1 EXECUTION VERSION AMENDMENT NO. 1 TO RIGHTS AGREEMENT This Amendment No. 1 to Rights Agreement (the “Amendment”), dated as of July 26, 2016, to the Rights Agreement (as amended from time to time, the “Rights Agreement”), dated as of March 3, 2009, between Sequenom, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company
July 27, 2016	EX-2.1	AGREEMENT AND PLAN OF MERGER SEQUENOM, INC., a Delaware corporation; LABORATORY CORPORATION OF AMERICA HOLDINGS, a Delaware corporation; and SAVOY ACQUISITION CORP., a Delaware corporation Dated as of July 26, 2016 TABLE OF CONTENTS Page SECTION 1. T EX-2.1 Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER among: SEQUENOM, INC., a Delaware corporation; LABORATORY CORPORATION OF AMERICA HOLDINGS, a Delaware corporation; and SAVOY ACQUISITION CORP., a Delaware corporation Dated as of July 26, 2016 TABLE OF CONTENTS Page SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser into
July 27, 2016	SC14D9C	Sequenom SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share, including associated preferred stock purchase rights (Titl
July 27, 2016	SC14D9C	Sequenom SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SEQUENOM, INC. (Name of Subject Company) SEQUENOM, INC. (Name of Person Filing Statement) Common Stock, $0.001 par value per share, including associated preferred stock purchase rights (Titl
July 27, 2016	EX-99.I	LABCORP ANNOUNCES AGREEMENT TO ACQUIRE SEQUENOM Acquisition Creates Market Leader in NIPT, Women’s Health and Reproductive Genetics LabCorp CEO: ‘This is exactly the kind of strategic acquisition that LabCorp seeks’ EX-99.I 2 d200206dex99i.htm EX-99.I Exhibit (i) FOR IMMEDIATE RELEASE LabCorp Contact: Paul Surdez, Vice President, Investor Relations (investors) 336-436-5076 [email protected] Pattie Kushner, Vice President, Corporate Communications (media) 336-436-8263 [email protected] Sequenom Contact: Carolyn Beaver, Senior Vice President and Chief Financial Officer (investors) 858-202-9028 investorrelati
July 27, 2016	EX-99.II	July 27, 2016 EX-99.II 3 d200206dex99ii.htm EX-99.II Exhibit (ii) July 27, 2016 Dear Sequenom Employees, I have important, positive news to share with you about a significant announcement we made this morning describing LabCorp’s intent to acquire Sequenom. Together, we have revolutionized prenatal care and built a market-leading NIPT company. Equally significant, we positively impact patient lives each and eve
June 17, 2016	EX-99.1	Sequenom, Inc. 2006 Equity Incentive Plan Approved By Board: April 10, 2006 Approved By Stockholders: May 31, 2006 Amended By Stockholders: May 29, 2008 Amended By Stockholders: June 14, 2010 Amended By Stockholders: June 15, 2011 Amended By Stockhol Exhibit Sequenom, Inc. 2006 Equity Incentive Plan Approved By Board: April 10, 2006 Approved By Stockholders: May 31, 2006 Amended By Stockholders: May 29, 2008 Amended By Stockholders: June 14, 2010 Amended By Stockholders: June 15, 2011 Amended By Stockholders: June 11, 2012 Amended By Stockholders: June 11, 2013 Amended By Stockholders: June 15, 2016 Termination Date: April 14, 2021 (Adjusted t
June 17, 2016	EX-3.1	Amendment to Restated Bylaws, as Amended, of Sequenom, Inc. Exhibit Amendment to Restated Bylaws, as Amended, of Sequenom, Inc. The Restated Bylaws, as amended (the ? Bylaws ?), of Sequenom, Inc., a Delaware corporation (the ? Company ?), are hereby amended as follows, effective upon the execution of this amendment by the Secretary or Assistant Secretary of the Company: Article III, Section 13, is hereby deleted in its entirety and replaced with the follow
June 17, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K 1 a8-kannualreport2016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2016 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorp
May 4, 2016	10-Q	Sequenom FORM 10-Q (Quarterly Report) 10-Q 1 sqnm2016q110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number
May 4, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission File Num
May 4, 2016	EX-99.1	SEQUENOM, INC. REPORTS FIRST QUARTER 2016 RESULTS Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul Goodson Senior Director, Investor Relations and Corporate Communications Sequenom, Inc. 858-202-9427 [email protected] SEQUENOM, INC. REPORTS FIRST QUARTER 2016 RESULTS SAN DIEGO, Calif. - May 4, 2016 - Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innova
April 27, 2016	DEFA14A	Sequenom DEFA14A DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 27, 2016	DEF 14A	Sequenom DEF 14A DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 22, 2016	8-K/A	Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2016 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission File N
April 22, 2016	EX-99.1	Sequenom Completes Consolidation of North Carolina Operations EX-99.1 2 ex991-ncsalepressrelease.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE Sequenom Contact: Paul Goodson Investor Relations Sequenom, Inc. 858-202-9427 [email protected] Sequenom Completes Consolidation of North Carolina Operations San Diego, April 19, 2016 - Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative prod
April 15, 2016	PRE 14A	Sequenom PRE 14A PRE 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 24, 2016	EX-1	JOINT FILING AGREEMENT EX-1 2 sqnm13dexhibit1v1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated March 24, 2016 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Secur
March 24, 2016	SC 13D	SQNM / Sequenom, Inc. / Camber Capital Management LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Sequenom, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 817337405 (CUSIP Number) Camber Capital Management LLC, 101 Huntington Avenue, Suite 2101, Boston, MA 02199 617-717-6600 (Name, Address and Telephone Number of Person Authorized t
March 9, 2016	10-K/A	Sequenom 10-K/A (Annual Report) 10-K/A 1 sqnm10ka2015.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
March 3, 2016	10-K	Sequenom 10-K (Annual Report) 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM, IN
March 3, 2016	EX-21.1	SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Sequenom Biosciences (India) Pvt. Ltd India Sequenom Center for Molecular Medicine, LLC, Michigan, United States
March 3, 2016	EX-10.30	POOLED PATENTS AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406. POOLED PATENTS AGREEMENT This Pooled Patents Agreement (the “Agreement”) is made and entered as of 11:59 P.M. Pacific Time on December 2, 2014 (such date and time the “Effective Date”) by and among: Illumina Inc., a Delaware corporati
March 2, 2016	EX-99.1	SEQUENOM, INC. REPORTS 2015 FINANCIAL RESULTS EX-99.1 2 ex991sqnm10-k2015earningsr.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul Goodson Rachel Lipsitz Senior Director, Investor Relations and Corporate Communications Media Contact Sequenom, Inc. inVentiv Health PR Group 858-202-9427 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS 2015 FINANCIAL RESULTS SAN DIEGO, March
March 2, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a201510-k8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2016 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporat
February 16, 2016	SC 13G/A	SQNM / Sequenom, Inc. / Palo Alto Investors, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Sequenom Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 817337405 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i
February 12, 2016	EX-1	JOINT FILING AGREEMENT EX-1 2 cambersqnm13gaexh2015v1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 12, 2016 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United Sta
February 12, 2016	SC 13G/A	SQNM / Sequenom, Inc. / Camber Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Sequenom, Inc. (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securities) 817337405 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
February 11, 2016	SC 13G/A	SQNM / Sequenom, Inc. / VANGUARD GROUP INC Passive Investment sequenominc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: Sequenom Inc Title of Class of Securities: Common Stock CUSIP Number: 817337405 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the appropriate box to designat
January 28, 2016	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events 8-K 1 a8-kamendedbylaws.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2016 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of in
January 28, 2016	EX-3.1	Amendment to Restated Bylaws, as Amended, of Sequenom, Inc. Exhibit Amendment to Restated Bylaws, as Amended, of Sequenom, Inc. The Restated Bylaws, as amended (the ? Bylaws ?), of Sequenom, Inc., a Delaware corporation (the ? Company ?), are hereby amended as follows, effective upon the execution of this amendment by the Secretary or Assistant Secretary of the Company: A new Article XI, Section 1 is hereby added to the Bylaws, which shall read in its enti
January 13, 2016	EX-99.1	SEQUENOM, INC. ANNOUNCES RESTRUCTURING: PLANS SALE OF NORTH CAROLINA OPERATIONS AND INITIATIVES TO IMPROVE EFFICIENCIES Exhibit FOR IMMEDIATE RELEASE Sequenom Contact: Paul Goodson Rachel Lipsitz Investor Relations Media Contact Sequenom, Inc.
January 13, 2016	8-K	Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events 8-K 1 a8-kcorprestructuring.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2016 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of
January 11, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 d120851d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2016 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of inco
January 11, 2016	EX-99.1	SEQUENOM, INC. ANNOUNCES PRELIMINARY 2015 RESULTS, PROVIDES UPDATE ON MaterniT® GENOME EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contact: Paul Goodson Rachel Lipsitz Investor Relations Media Contact Sequenom, Inc. inVentiv Health PR Group 858-202-9427 858-449-9575 [email protected] [email protected] SEQUENOM, INC. ANNOUNCES PRELIMINARY 2015 RESULTS, PROVIDES UPDATE ON MaterniT? GENOME SAN DIEGO, Calif. ? Jan. 11, 2016 ? Sequenom, Inc. (NASDAQ: SQNM), a
December 11, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission Fil
December 11, 2015	EX-99.1	SEQUENOM ANNOUNCES APPOINTMENT OF DIRK VAN DEN BOOM AS PRESIDENT AND CHIEF EXECUTIVE OFFICER Exhibit FOR IMMEDIATE RELEASE Sequenom Contact: Paul Goodson Rachel Kennedy Investor Relations Media Contact Sequenom, Inc.
November 5, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM
November 5, 2015	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2015 EX-99.1 2 sequenom3q15xearningsrele.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul Goodson Rachel Kennedy Senior Director, Investor Relations and Corporate Communications Media Contact Sequenom, Inc. inVentiv Health PR Group 858-202-9427 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER O
November 5, 2015	8-K	Sequenom 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission Fil
October 13, 2015	SC 13G/A	SQNM / Sequenom, Inc. / Camber Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Sequenom, Inc. (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securities) 817337405 (CUSIP Number) October 1, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
October 13, 2015	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated October 13, 2015 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
October 2, 2015	424B3	PROSPECTUS Common Stock Preferred Stock Debt Securities S-3 This filing is made pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No 333-206655 PROSPECTUS $300,000,000 Common Stock Preferred Stock Debt Securities Warrants From time to time, we may offer up to $300,000,000 of any combination of the securities described in this prospectus in one or more offerings.
October 2, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission File
October 2, 2015	EX-99.1	/s/ Kenneth F. Buechler By: Kenneth F. Buechler, PhD Chairman of the Board of Directors EX-99.1 2 ex991.htm EXHIBIT 99.1 September 18, 2015 William J. Welch 173 South Nardo Avenue Solana Beach, CA 92121 RE: Separation Agreement Dear Bill, This letter sets forth the terms and conditions of our agreement (the “Agreement”) regarding the separation of your employment with Sequenom, Inc. (the “Company”). This Agreement will become effective on the Effective Date as defined in Section 10 h
October 1, 2015	CORRESP	Sequenom ESP CORRESP Sequenom, Inc. 3595 John Hopkins Court San Diego, CA 92121 October 1, 2015 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Sequenom, Inc. Registration Statement on Form S-3 Filed August 28, 2015 File No. 333-206655 Ladies and Gentlemen: Pursuant to Rules 460 and 461 under the Securitie
September 28, 2015	EX-99.1	INVESTOR + ANALYST DAY EX-99.1 Exhibit 99.1 INVESTOR + ANALYST DAY September 28, 2015 Welcome Dirk van den Boom, PhD Interim President and CEO Chief Scientific & Strategy Officer 2 Forward-looking statements Except for historical information, matters set forth in this presentation, including statements regarding Sequenom?s plans, potential, opportunities, financial or other expectations, projections, goals, objectives,
September 28, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission F
September 28, 2015	CORRESP	Sequenom ESP CORRESP September 28, 2015 Via EDGAR and FedEx Mr. Kevin Kuhar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3030 Washington, D.C. 20549 Re: Sequenom, Inc. Form 10-K for Fiscal Year Ended December 31, 2014 Filed March 10, 2015 File No. 000-29101 Ladies and Gentlemen: On behalf of Sequenom, Inc. (the ? Company ?), this letter is being
September 24, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 a8kceochange.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incor
September 24, 2015	EX-99.1	Sequenom Announces Appointment of Dirk van den Boom as Interim President and CEO Exhibit FOR IMMEDIATE RELEASE Sequenom Contacts: Carolyn Beaver Rachel Kennedy Senior Vice President and Chief Financial Officer Media Contact Sequenom, Inc.
September 14, 2015	CORRESP	Sequenom ESP CORRESP September 14, 2015 Via EDGAR and FedEx Mr. Kevin Kuhar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3030 Washington, D.C. 20549 Re: Sequenom, Inc. Form 10-K for Fiscal Year Ended December 31, 2014 Filed March 10, 2015 File No. 000-29101 Ladies and Gentlemen: On behalf of Sequenom, Inc. (the ? Company ?), this letter is being
August 28, 2015	S-3	As filed with the Securities and Exchange Commission on August 28, 2015 As filed with the Securities and Exchange Commission on August 28, 2015 Registration No.
August 28, 2015	EX-4.7	SEQUENOM, INC. ________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [__], 20___ SEQUENOM, INC. FORM OF COMMON STOCK WARRANT AGREEMENT EXHIBIT 4.7 SEQUENOM, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [], 20 SEQUENOM, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between SEQUENOM, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corp
August 28, 2015	EX-4.9	SEQUENOM, INC. ________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [__], 20___ SEQUENOM, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT EX-4.9 5 exhibit49formofdebtsecurit.htm EXHIBIT 4.9 FORM OF DEBT SECURITIES WARRANTS AGREEMENT EXHIBIT 4.9 SEQUENOM, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [], 20 SEQUENOM, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT Debt Securities Warrant Agreement (this “Agreement”), dated as of between Sequenom, Inc., a Delaware corporation (the “Company”), and , a
August 28, 2015	EX-4.8	SEQUENOM, INC. ________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [__], 20___ SEQUENOM, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT EXHIBIT 4.8 SEQUENOM, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [], 20 SEQUENOM, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between SEQUENOM, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and havi
August 28, 2015	EX-4.4	SEQUENOM, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt Securities EX-4.4 2 exhibit44formofindenturebe.htm EXHIBIT 4.4 FORM OF INDENTURE, BETWEEN THE REGISTRANT AND ONE OR MORE TRUSTEES EXHIBIT 4.4 SEQUENOM, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Sect
August 28, 2015	EX-12.1	Statement Regarding Computation of Ratios of Earnings to Fixed Charges and Ratio of Combined Fixed Charges and Preference Dividends to Earnings Year Ended Six Months Ended June 30, 2015 (dollars in 000's) 2010 2011 2012 2013 2014 Earnings: Earnings ( EXHIBIT 12.1 Statement Regarding Computation of Ratios of Earnings to Fixed Charges and Ratio of Combined Fixed Charges and Preference Dividends to Earnings Year Ended Six Months Ended June 30, 2015 (dollars in 000's) 2010 2011 2012 2013 2014 Earnings: Earnings (loss) from continuing operations before income taxes (127,349 ) (82,107 ) (117,975 ) (110,920 ) (22,040 ) 5,396 Add: fixed charges 1,827
August 6, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a2015q28-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporati
August 6, 2015	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2015 Improved Cash Burn with Increased Patent Pool Licensing Revenues Sequenom2Q15EarningsRelease Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Carolyn Beaver Rachel Kennedy Senior Vice President and Chief Financial Officer Media Contact Sequenom, Inc. inVentiv Health PR Group 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2015 Improved Cash Burn wi
August 6, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM, INC
July 10, 2015	EX-10.43	POOLED PATENTS AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406. POOLED PATENTS AGREEMENT This Pooled Patents Agreement (the ?Agreement?) is made and entered as of 11:59 P.M. Pacific Time on December 2, 2014 (such date and time the ?Effective Date?) by and among: Illumina Inc., a Delaware corporati
July 10, 2015	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 10-K/A 1 sqnm10-ka123114.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr
June 25, 2015	EX-16.1	June 23, 2015 SQNM Change in Auditor Exhibit 16.1 June 23, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated June 19, 2015, of Sequenom, Inc. and are in agreement with the statements contained in the second sentence of paragraph 1 and the entirety of paragraphs 2, 3 and 4 of Item 4.01 (a), Changes in Registrant?s Certif
June 25, 2015	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 sqnm8-kchangeinauditor.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of
June 19, 2015	EX-3.1	CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION SEQUENOM, INC. EX-3.1 2 exhibit31.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF SEQUENOM, INC. Sequenom, Inc., a Delaware corporation (the “Company”), does hereby certify that: First: The name of the Company is Sequenom, Inc. Second: The date on which the Certificate of Incorporation of the Company was originally filed with the Secretary of State of the State of
June 19, 2015	8-K	Sequenom 8-K (Current Report/Significant Event) SQNM8K061815 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 17, 2015 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission F
June 19, 2015	EX-99.1	Sequenom Contacts: Carolyn Beaver Rachel Kennedy Senior Vice President and Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUE EX-99.1 3 exhibit991.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Carolyn Beaver Rachel Kennedy Senior Vice President and Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM WELCOMES CATHERINE J. MACKEY, PH.D., TO BOARD OF DIRECTORS SAN DIEGO, Cal
June 11, 2015	8-K	Sequenom 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 9, 2015 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Number
June 11, 2015	EX-4.1	SEQUENOM, INC. AS ISSUER 5.00% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2018 DATED AS OF JUNE 9, 2015 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE EX-4.1 Exhibit 4.1 Execution Version SEQUENOM, INC. AS ISSUER 5.00% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2018 INDENTURE DATED AS OF JUNE 9, 2015 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE Execution Version TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 5 Section 1.01 Definitions. 5 Section 1.02 Other Definitions. 18 Section 1.03 [Reserved]. 19 Section 1.04 Rule
June 4, 2015	EX-99.1	Sequenom Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Carolyn Beaver Rachel Kennedy Senior Vice President and Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] Sequenom Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes SAN DIEGO, Calif
June 4, 2015	EX-4.1	SEQUENOM, INC. AS ISSUER 5.00% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2018 DATED AS OF JUNE [ ], 2015 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 5 Section 1.01 Definiti EX-4.1 2 d937133dex41.htm EX-4.1 Exhibit 4.1 SEQUENOM, INC. AS ISSUER 5.00% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2018 INDENTURE DATED AS OF JUNE [ ], 2015 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 5 Section 1.01 Definitions 5 Section 1.02 Other Definitions 18 Section 1.03 [Reserved] 19 Section 1.04 Rules of Constr
June 4, 2015	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events 8-K 1 d937133d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 4, 2015 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (C
May 28, 2015	SD	Sequenom SD Conflict Mineral Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 7, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM, IN
May 6, 2015	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2015 Expanded Testing Menu with VisibiliT™ and HerediT ® Universal Sequenom1Q15EarningsReleasev92 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Carolyn Beaver Rachel Kennedy Senior Vice President and Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2015 Expanded Testing M
May 6, 2015	8-K	Sequenom 8-K (Current Report/Significant Event) 2015 Q1 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission
April 28, 2015	DEF 14A	Sequenom PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 28, 2015	DEFA14A	Sequenom DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru
April 17, 2015	PRE 14A	Sequenom PRELIMINARY PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 16, 2015	8-K	Sequenom FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 10, 2015 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File
March 10, 2015	EX-10.43	POOLED PATENTS AGREEMENT EX-10.43 2 a1043pooledpatentsagreemen.htm EXHIBIT 10.43 POOLED PATENTS AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406. POOLED PATENTS AGREEMENT This Pooled Patents Agreement (the “Agreement”) is made and entered as of 11:59 P.M. Pacific Time on December 2, 2014 (such date
March 10, 2015	EX-10.44	SEQUENOM DRAFT SEPTEMBER 8, 2014 CONFIDENTIAL DRAFT FOR DISCUSSION UNDER RULE 408 EX-10.44 3 a1044settlementagreementda.htm EXHIBIT 10.44 SETTLEMENT AGREEMENT SEQUENOM DRAFT SEPTEMBER 8, 2014 CONFIDENTIAL DRAFT FOR DISCUSSION UNDER RULE 408 SUBJECT TO REVIEW AND APPROVAL BY ALL PARTIES AND THEIR COUNSEL SETTLEMENT AGREEMENT By and among Illumina Inc., Sequenom, Inc., Sequenom Center for Molecular Medicine, LLC, and Verinata Health, Inc. Dated as of December 2, 2014 SETTLEMENT A
March 10, 2015	EX-21.1	SUBSIDIARIES OF THE REGISTRANT EX-21.1 6 ex211subsidiariesofregistr.htm EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Sequenom Hong Kong, Ltd Hong Kong Sequenom Biosciences (India) Pvt. Ltd India Sequenom Center for Molecular Medicine, LLC, Michigan, United States
March 10, 2015	EX-10.46	1 of 6 EX-10.46 5 a1046agreementdateddecembe.htm EXHIBIT 10.46 CHINESE UNIVERSITY OF HONG KONG AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406. AGREEMENT THIS AGREEMENT (this “Agreement”) is made and entered into as of December 2, 2014 (the “Effective Date”) by and between Sequen
March 10, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 sqnm201410-k.htm 10-K SEQUENOM INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi
March 10, 2015	EX-10.45	Amended and Restated Sale and Supply Agreement EX-10.45 4 a1045amendedandrestatedsal.htm EXHIBIT 10.45 AMENDED AND RESTATED SALE AND SUPPLY AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission.Confidential Treatment Requested Under17 C.F.R. Sections 200.80(b)(4) and 230.406. Amended and Restated Sale and Supply Agreement This Amended and Restated Sales and Supply Agreement (“Agreement”) by and between Illu
March 4, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission File N
March 4, 2015	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2014 Record annual diagnostics revenues and profitability in 2014 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Carolyn Beaver Rachel Kennedy Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2014 Record annual diagnostics revenues and profitability in 201
February 18, 2015	SC 13G/A	SQNM / Sequenom, Inc. / Palo Alto Investors, LLC - SC 13G/A Passive Investment SC 13G/A 1 Sequenom13Ga3.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Sequenom Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 817337405 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
February 13, 2015	SC 13G/A	SQNM / Sequenom, Inc. / Camber Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Sequenom, Inc. (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securities) 817337405 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
February 13, 2015	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 13, 2015 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
February 11, 2015	SC 13G/A	SQNM / Sequenom, Inc. / VANGUARD GROUP INC Passive Investment sequenominc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Sequenom Inc Title of Class of Securities: Common Stock CUSIP Number: 817337405 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropriate box to designat
January 23, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 20, 2015 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission Fi
January 12, 2015	EX-99.1	2015 Sequenom. All rights reserved. EX-99.1 © 2015 Sequenom. All rights reserved. Interpreting the genome to improve your life JP Morgan Healthcare Conference January 12-15, 2015 Bill Welch, CEO Exhibit 99.1 © 2015 Sequenom. All rights reserved. 2 Except for historical information, matters set forth in this presentation, including statements regarding Sequenom’s plans, potential, opportunities, financial or other expectations, proje
January 12, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 d850326d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2015 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorpora
January 9, 2015	SC 13G/A	SQNM / Sequenom, Inc. / VANGUARD GROUP INC Passive Investment sequenominc2.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Sequenom Inc Title of Class of Securities: Common Stock CUSIP Number: 817337405 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropriate box to designat
December 23, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission F
December 5, 2014	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2014 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commissio
November 10, 2014	EX-10.1	PATENT PURCHASE AGREEMENT EX-10.1 2 ex101patentpurcahseagreeme.htm EXHIBIT PATENT PURCAHSE AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 PATENT PURCHASE AGREEMENT THIS PATENT PURCHASE AGREEMENT (this “Agreement”) dated as of September 30, 2014 (the “Effective Date”), is entered into between ISI
November 10, 2014	EX-10.2	SECOND AMENDMENT TO LEASE EX-10.2 3 ex102leaseamendment.htm EXHIBIT LEASE AMENDMENT SECOND AMENDMENT TO LEASE This SECOND AMENDMENT TO LEASE ("Second Amendment") is made and entered into as of the 25th day of September, 2014, by and between TPSC IV LLC, a Delaware limited liability company ("Landlord"), and SEQUENOM, INC., a Delaware corporation ("Tenant"). RECITALS: A. Landlord and Tenant entered into that certain Lease d
November 10, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 sqnm201410-qq3.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
November 4, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2014 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commissio
November 4, 2014	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2014 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Carolyn Beaver Rachel Kennedy Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2014 • 14% increase in revenue from the prior year third quarter • 50% i
October 6, 2014	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2014 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commiss
August 1, 2014	EX-10.4	First amendment to AGREEMENT FOR SERVICES EX-10.4 6 ex104firstamendmenttoagree.htm EXHIBIT 10.4 FIRST AMENDMENT TO AGREEMENT FOR SERVICES First amendment to AGREEMENT FOR SERVICES THIS FIRST AMENDMENT TO AGREEMENT FOR SERVICES (“First Amended Agreement”) is entered into as of the last date of signature below, by and between Sequenom Center for Molecular Medicine, LLC d/b/a Sequenom Laboratories (“SCMM”) and Quest Diagnostics Incorporated
August 1, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM, INC
August 1, 2014	EX-10.1	LICENSE AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 LICENSE AGREEMENT This License Agreement (the ?Agreement?) is entered into as of May 30, 2014 (the ?Effective Date?), by and between BioSciences Acquisition Company, a Delaware corporation (?Purchaser?), with its principal place of b
August 1, 2014	EX-10.2	SUPPLY AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 SUPPLY AGREEMENT This Supply Agreement (the ?Agreement?) is entered into as of May 30, 2014, (the ?Effective Date?), by and between BioSciences Acquisition Company, a Delaware corporation (?Supplier?), with its principal place of bus
August 1, 2014	EX-10.5	LICENSE AGREEMENT ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 LICENSE AGREEMENT THIS LICENSE AGREEMENT (this ?Agreement?) dated as of June 13, 2014 (the ?Effective Date?), is entered into between SEQUENOM, INC., a Delaware corporation (?Sequenom?), having a place of business at 3595 John Hopkin
August 1, 2014	EX-10.3	AGREEMENT FOR SERVICES EX-10.3 5 ex103agreementforservicesd.htm EXHIBIT 10.3 AGREEMENT FOR SERVICES ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 QuestLaboratory Client Bill Agreement final AGREEMENT FOR SERVICES THIS AGREEMENT FOR SERVICES (“Agreement”) is entered into as of the last date of signatur
August 1, 2014	EX-2.1	STOCK AND ASSET PURCHASE AGREEMENT by and between BIOSCIENCES ACQUISITION COMPANY SEQUENOM, INC. Dated as of May 30, 2014 1. *Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 STOCK AND ASSET PURCHASE AGREEMENT by and between BIOSCIENCES ACQUISITION COMPANY and SEQUENOM, INC. Dated as of May 30, 2014 *Confidential Treatment Requested -iv- Table of Contents Page -i- SECTION 1. Purchase and Sale 1 1.1 A
July 29, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 29, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
July 29, 2014	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2014 62% Revenue Growth as Reimbursement and Testing Volumes Improve EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Carolyn Beaver Rachel Kennedy Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2014 62% Revenue Growth as Reimbursement and Testing Volumes Improve SA
June 16, 2014	8-K	Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2014 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission F
June 11, 2014	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2014 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission F
June 4, 2014	EX-99.1	SEQUENOM, INC. INTRODUCTION TO PRO FORMA CONSOLIDATED FINANCIAL INFORMATION EX-99.1 2 d738303dex991.htm EX-99.1 Exhibit 99.1 SEQUENOM, INC. INTRODUCTION TO PRO FORMA CONSOLIDATED FINANCIAL INFORMATION (Unaudited) The accompanying unaudited pro forma condensed consolidated statement of operations for three months ended March 31, 2014 and the years ended December 31, 2013, 2012 and 2011 give effect to the disposition of certain assets related to the Company’s Bioscience bus
June 4, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2014 SEQUENOM, INC. (Exact name of registrant as specified in its charter) Delaware 000-29101 77-0365889 (State or other jurisdiction of incorporation) (Commission File Nu
May 30, 2014	EX-1.01	Sequenom, Inc. Conflict Minerals Report For the Year Ended December 31, 2013 EX-1.01 2 exhibit101-conflictmineral.htm EXHIBIT - CONFLICT MINERALS REPORT Exhibit 1.01 Sequenom, Inc. Conflict Minerals Report For the Year Ended December 31, 2013 This report has been prepared by Sequenom management and the information includes the activities as used in this report, the words “we,” “us,” “our,” the “Company,” and “Sequenom” refer to Sequenom, Inc. and its wholly-owned subsidiar
May 30, 2014	SD	- SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report SEQUENOM, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-29101 77-0365889 (State or other jurisdiction of incorporation or organization) Commission File Number (I.R.S. Employer Identification Number) 3595 John Hopkins Court San Diego, California 92121 (Address of
May 2, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 1, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 1, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 1, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM, IN
May 1, 2014	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2014 20% Year-Over-Year Increase in Total Revenues Led By Continued Growth in Diagnostic Services EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul V. Maier Rachel Kennedy Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2014 20% Year-Over-Year Increase in Total Revenues Led By Continued Growt
April 25, 2014	DEF 14A	- DEF 14A DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 25, 2014	DEFA14A	- DEFA14A DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 14, 2014	8-K	Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 7, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File
March 7, 2014	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 4, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File N
March 6, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 4, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File
March 6, 2014	EX-99.1	SEQUENOM ANNOUNCES CHANGES IN COMPANY LEADERSHIP Harry Hixson to Retire as Sequenom CEO Board Names William Welch as next CEO Dirk Van Den Boom Promoted to Chief Scientific and Strategy Officer Paul V. Maier to retire as CFO, Carolyn D. Beaver to ass EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul V. Maier Rachel Kennedy CFO Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM ANNOUNCES CHANGES IN COMPANY LEADERSHIP Harry Hixson to Retire as Sequenom CEO Board Names William Welch as next CEO Dirk Van Den Boom Promoted to Chi
February 28, 2014	10-K/A	Sequenom 10-K/A (Annual Report) SQNM 2013 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File
February 27, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM, INC. (E
February 27, 2014	EX-10.23	SEQUENOM, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 10.23 SEQUENOM, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Board of Directors (the ?Board?) of Sequenom, Inc. (the ?Company?) and the Nominating and Corporate Governance Committee of the Board adopted the following compensation program for non-employee directors of the Board. Pursuant to this program, each member of the Board who is not an employee or an officer of the Company will
February 27, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 27, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File N
February 27, 2014	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF 2013 Record quarterly and annual revenues; annual growth of 81% over prior year EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul V. Maier Rachel Kennedy Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF 2013 Record quarterly and annual revenues; annual growth o
February 27, 2014	EX-21.1	SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Sequenom GmbH Germany Sequenom K.K. Japan Sequenom Hong Kong, Ltd Hong Kong Sequenom Biosciences (India) Pvt. Ltd India Sequenom Center for Molecular Medicine, LLC, Michigan, United States
February 14, 2014	SC 13G/A	SQNM / Sequenom, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G AMENDMENT FILING Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2014	SC 13G/A	SQNM / Sequenom, Inc. / Palo Alto Investors, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Sequenom Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 817337405 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i
February 14, 2014	SC 13G/A	SQNM / Sequenom, Inc. / SAC Capital Advisors LP - SCHEDULE 13G/A, #2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SEQUENOM, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 817337405 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 12, 2014	SC 13G/A	SQNM / Sequenom, Inc. / SECTORAL ASSET MANAGEMENT INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* SEQUENOM INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 817337405 (CUSIP Number) DECEMBER 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 11, 2014	SC 13G/A	SQNM / Sequenom, Inc. / VANGUARD GROUP INC Passive Investment sequenominc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Sequenom Inc Title of Class of Securities: Common Stock CUSIP Number: 817337405 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to designat
February 3, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 3, 2014	EX-99.2	EMPLOYMENT AGREEMENT EX-99.2 3 d666495dex992.htm EX 99.2 Exhibit 99.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of January 29, 2014 (the “Effective Date”) by and between Sequenom, Inc., a Delaware corporation with offices at 3595 John Hopkins Court, San Diego, California 92121 (“Sequenom”), and Dirk van den Boom, Ph.D. (the “Executive’’). WHEREAS, the Executive is currently employed a
February 3, 2014	EX-99.1	EMPLOYMENT AGREEMENT EX-99.1 2 d666495dex991.htm EX 99.1 Exhibit 99.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of January 29, 2014 (the “Effective Date”) by and between Sequenom, Inc., a Delaware corporation with offices at 3595 John Hopkins Court, San Diego, California 92121 (“Sequenom”), and William J. Welch (the “Executive’’). WHEREAS, the Executive is currently employed as an off
January 13, 2014	EX-99.1	SEQUENOM ANNOUNCES PRELIMINARY 2013 OPERATIONAL HIGHLIGHTS AND OBJECTIVES FOR 2014 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul Maier Rachel Kennedy Chief Financial Officer Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM ANNOUNCES PRELIMINARY 2013 OPERATIONAL HIGHLIGHTS AND OBJECTIVES FOR 2014 SAN DIEGO, Calif. – January 12, 2014 - Sequenom, Inc. (NASD
January 13, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 12, 2014 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission Fi
December 16, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 12, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission F
December 5, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 3, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 12, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 7, 2013	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2013 Announces Record Revenue for the Quarter EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul Maier Chief Financial Officer Sequenom, Inc. 858-202-9028 [email protected] Rachel Kennedy Media Contact Chandler Chicco Agency 858-449-9575 [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2013 Announces Record Revenue for the Quarter SAN DIEGO, Calif. – November 7
November 7, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM
November 7, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 7, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 31, 2013	8-K	Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission Fi
October 21, 2013	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 16, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Number
October 21, 2013	EX-99.1	United States District Court For the Northern District of California IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA ARIA DIAGNOSTICS, INC., Plaintiff, v. SEQUENOM, INC., Defendant/Counterclaimant. / No. C 11-06391 SI CLAI EX-99.1 Exhibit 99.1 United States District Court For the Northern District of California IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA ARIA DIAGNOSTICS, INC., Plaintiff, v. SEQUENOM, INC., Defendant/Counterclaimant. / No. C 11-06391 SI CLAIM CONSTRUCTION ORDER NATERA, INC. and DNA DIAGNOSTICS CENTER, INC., Plaintiffs/Counterclaim-Defendants, v. SEQUENOM, INC. and ISI
September 23, 2013	EX-99.1	SEQUENOM ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES FOR ITS GENETIC ANALYSIS BUSINESS SEGMENT Jefferies LLC Engaged as Financial Advisor EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Paul Maier Rachel Kennedy CFO Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES FOR ITS GENETIC ANALYSIS BUSINESS SEGMENT Jefferies LLC Engaged as Financial Advisor SAN DIEGO, Calif. – Sept.
September 23, 2013	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission
August 19, 2013	8-K	Costs Associated with Exit or Disposal Activities - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 19, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Num
July 24, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File
July 24, 2013	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2013 Continued Growth in Testing Volumes as NIPT Market Leader EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Marcy Graham Rachel Kennedy Senior Director, Investor Relations & Corp Comm Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 858-449-9575 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2013 Continued Growth in Testing Volumes as NIPT Market Lea
July 24, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM, INC
June 21, 2013	S-8	- FORM S-8 S-8 1 d557022ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on June 21, 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SEQUENOM, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 77-0365889 (State or other jurisdiction of Incorporation or or
June 21, 2013	EX-99.2	SEQUENOM, INC. 1999 EMPLOYEE STOCK PURCHASE PLAN AMENDED AND RESTATED EFFECTIVE JUNE 11, 2013 ADOPTED BY THE BOARD OF DIRECTORS: MARCH 5, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2013 EX-99.2 5 d557022dex992.htm EX-99.2 Exhibit 99.2 SEQUENOM, INC. 1999 EMPLOYEE STOCK PURCHASE PLAN AMENDED AND RESTATED EFFECTIVE JUNE 11, 2013 ADOPTED BY THE BOARD OF DIRECTORS: MARCH 5, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 11, 2013 1. GENERAL. (a) The purpose of the Plan is to provide a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an
June 21, 2013	EX-99.1	Sequenom, Inc. 2006 Equity Incentive Plan Approved By Board: April 10, 2006 Approved By Stockholders: May 31, 2006 Amended By Stockholders: May 29, 2008 Amended By Stockholders: June 14, 2010 Amended By Stockholders: June 15, 2011 Amended By Stockhol EX-99.1 4 d557022dex991.htm EX-99.1 Exhibit 99.1 Sequenom, Inc. 2006 Equity Incentive Plan Approved By Board: April 10, 2006 Approved By Stockholders: May 31, 2006 Amended By Stockholders: May 29, 2008 Amended By Stockholders: June 14, 2010 Amended By Stockholders: June 15, 2011 Amended By Stockholders: June 11, 2012 Amended By Stockholders: June 11, 2013 Termination Date: April 14, 2021 (Adjusted
June 17, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 11, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File
June 13, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 11, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File
June 11, 2013	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-
June 11, 2013	EX-10.57	DATED 29 November 2012 ISIS INNOVATION LIMITED AND FOURTH AMENDMENT AGREEMENT EX-10.57 2 d551007dex1057.htm EXHIBIT 10.57 Exhibit 10.57 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 DATED 29 November 2012 ISIS INNOVATION LIMITED AND SEQUENOM, INC. FOURTH AMENDMENT AGREEMENT THIS FOURTH AMENDMENT AGREEMENT is made on 29 November, 2012 (The “Fourth Amendmen
June 7, 2013	CORRESP	- RESPONSE LETTER R. William Bowen Senior Vice President and General Counsel 858-202-9455 [email protected] June 7, 2013 Via EDGAR and FedEx Mr. Tim Buchmiller United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Re: Sequenom, Inc. Form 10-K for the fiscal year ended December 31, 2012 Filed April 2, 2013 File No.
May 9, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
May 9, 2013	EX-10.58	ASSIGNMENT AND ASSUMPTION OF LEASE EX-10.58 2 exh1058ebioscienceleaseass.htm EBIOSCIENCES LEASE ASSIGNMENT Exhibit 10.58 ASSIGNMENT AND ASSUMPTION OF LEASE This Assignment and Assumption of Lease (this "Agreement"), dated as of January 11, 2013 is by and between eBioscience, Inc., a California corporation having a place of business at 10255 Science Center Drive, San Diego, California 92121 ("Assignor"), and Sequenom, Inc., a Delawa
May 9, 2013	EX-99.1	Sequenom Contacts: Marcy Graham Jakob Jakobsen Senior Director, Investor Relations & Corp Comm Media Contact Sequenom, Inc Chandler Chicco Agency 858-202-9028 310-309-1003 [email protected] [email protected] SEQUENOM, INC. REPO Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Marcy Graham Jakob Jakobsen Senior Director, Investor Relations & Corp Comm Media Contact Sequenom, Inc Chandler Chicco Agency 858-202-9028 310-309-1003 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2013 158% Year-Over-Year Increase In Total Revenues Led By Continued
May 9, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 sqnm201310-qq1.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File
April 26, 2013	DEFA14A	- DEFA14A DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 26, 2013	DEF 14A	- DEF 14A DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 2, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29101 SEQUENOM, INC. (E
April 2, 2013	EX-10.56	Third Amendment to Sale and Supply Agreement EX-10.56 2 ex1056illuminaamendment.htm ILLUMINA AMENDMENT Exhibit 10.56 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Third Amendment to Sale and Supply Agreement Sequenom, Inc. (“SQNM”) and Illumina, Inc. (“Illumina”) entered into that certain Sale and Supply Agreement with an
April 2, 2013	EX-10.57	DATED 29 November 2012 ISIS INNOVATION LIMITED AND SEQUENOM, INC. FOURTH AMENDMENT EX-10.57 3 ex1057isisamendment.htm ISIS AMENDMENT *Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 DATED 29 November 2012 ISIS INNOVATION LIMITED AND SEQUENOM, INC. FOURTH AMENDMENT AGREEMENT * Confidential Treatment Requested 802573 v3/SD THIS FOURTH AMENDMENT AGREEMENT is made
April 2, 2013	EX-21.1	SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Sequenom?Gemini, Ltd. England and Wales Gemini Genomics, (UK) Ltd. England and Wales Gemini Genomics, Ltd. England and Wales Sequenom GmbH Germany Sequenom K.K. Japan Sequenom Hong Kong, Ltd Hong Kong Sequenom Biosciences (India) Pvt. Ltd India Sequenom Center for Molecular Medicine, LLC United States
March 18, 2013	NT 10-K	- NT 10-K NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR For Period Ended: December 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
March 7, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 7, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
March 7, 2013	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 5, 2013 SEQUENOM, INC. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-29101 77-0365889 (State or Other Jurisdiction of Incorporation) (Commission File Number) (
March 7, 2013	EX-99.1	SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF 2012 Diagnostic Services Now Largest Contributor to Total Revenues EX-99.1 2 d498845dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Sequenom Contacts: Marcy Graham Jakob Jakobsen Senior Director, Investor Relations & Corp Comm Media Contact Sequenom, Inc. Chandler Chicco Agency 858-202-9028 310-309-1003 [email protected] [email protected] SEQUENOM, INC. REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF 2012 Diagnostic

SQNM / Sequenom, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)